These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Forssbohm M; Loddenkemper R; Rieder HL Int J Tuberc Lung Dis; 2003 Oct; 7(10):973-9. PubMed ID: 14552568 [TBL] [Abstract][Full Text] [Related]
25. Mini epidemic of isoniazide resistant TB in rural TN: a need for supervised preventive therapy. Mehta J; Keith R; Al Hasan M; Ryland B; Roy T Tenn Med; 2009 Aug; 102(8):41-4. PubMed ID: 19691201 [TBL] [Abstract][Full Text] [Related]
26. Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime. Nolan CM Am J Respir Crit Care Med; 2003 Aug; 168(4):412-3. PubMed ID: 12912731 [No Abstract] [Full Text] [Related]
27. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. Shah AR; Agarwal SK; Shah KV Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118 [TBL] [Abstract][Full Text] [Related]
28. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Mohammed A; Myer L; Ehrlich R; Wood R; Cilliers F; Maartens G Int J Tuberc Lung Dis; 2007 Oct; 11(10):1114-20. PubMed ID: 17945069 [TBL] [Abstract][Full Text] [Related]
29. [30 years of isoniazid (INH) treatment]. Terracina S; Lewit T Harefuah; 1985 Feb; 108(4):213-6. PubMed ID: 4007674 [No Abstract] [Full Text] [Related]
30. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Fallab-Stubi CL; Zellweger JP; Sauty A; Uldry C; Iorillo D; Burnier M Int J Tuberc Lung Dis; 1998 Jul; 2(7):525-30. PubMed ID: 9661817 [TBL] [Abstract][Full Text] [Related]
31. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients. Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825 [TBL] [Abstract][Full Text] [Related]
32. More on the question of optimal chemotherapy in the presence of isoniazid resistance. Long R; Scalcini M Int J Tuberc Lung Dis; 2000 Sep; 4(9):890-4. PubMed ID: 10985663 [No Abstract] [Full Text] [Related]
33. Isoniazid prophylaxis in end-stage renal disease. Bal AM Transpl Infect Dis; 2006 Dec; 8(4):242-3; author reply 243. PubMed ID: 17116141 [No Abstract] [Full Text] [Related]
34. [Resistance and multiresistance to antitubercular drugs in Argentina and in other Latin American countries]. de Kantor IN; Latini O; Barrera L Medicina (B Aires); 1998; 58(2):202-8. PubMed ID: 9706257 [TBL] [Abstract][Full Text] [Related]
36. Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection. Yu WC; Lai ST; Chiu MC; Chau TN; Ng TK; Tam CM Int J Tuberc Lung Dis; 2006 Jul; 10(7):824-5. PubMed ID: 16850548 [No Abstract] [Full Text] [Related]
37. Anti-tuberculosis drug resistance and HIV co-infection in Phnom Penh, Cambodia. Sar B; Keo C; Leng C; Saman M; Min DC; Chan S; Monchy D; Sarthou JL Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):104-7. PubMed ID: 19323041 [TBL] [Abstract][Full Text] [Related]